Form 8-K - Current report:
SEC Accession No. 0001193125-24-152309
Filing Date
2024-06-03
Accepted
2024-06-03 06:18:31
Documents
17
Period of Report
2024-06-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d768276d8k.htm   iXBRL 8-K 37224
2 EX-10.1 d768276dex101.htm EX-10.1 169586
3 EX-10.2 d768276dex102.htm EX-10.2 84188
4 EX-99.1 d768276dex991.htm EX-99.1 19292
8 GRAPHIC g768276dsp59.jpg GRAPHIC 8515
  Complete submission text file 0001193125-24-152309.txt   528684

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA smmt-20240603.xsd EX-101.SCH 2855
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE smmt-20240603_lab.xml EX-101.LAB 17993
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE smmt-20240603_pre.xml EX-101.PRE 11264
20 EXTRACTED XBRL INSTANCE DOCUMENT d768276d8k_htm.xml XML 3639
Mailing Address 2882 SAND HILL ROAD SUITE 106 MENLO PARK CA 94025
Business Address 2882 SAND HILL ROAD SUITE 106 MENLO PARK CA 94025 650-460-8308
Summit Therapeutics Inc. (Filer) CIK: 0001599298 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36866 | Film No.: 241011916
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)